Which Ketamine Treatment Offers the Best Results for the Price?

What "Results for the Price" Means in Ketamine Therapy

Sticker prices don't tell you much, because no treatment helps everyone and not everyone starts in the same place. A cheaper course that rarely works is not a better deal than a pricier one that usually does. So instead of comparing what a course costs, compare what a result costs.

The cleanest way to do that is a unit price. On the standard depression questionnaire clinicians use, the PHQ-9, every patient's progress is measured in points: how far their score falls from the start of treatment to the end. Take the price of a full course, divide it by the average number of points it brings symptoms down, and you can estimate the cost of a single point of improvement. It is the same idea as checking price per ounce instead of price per package. The lower the number, the more improvement your money buys.

That calculation needs two honest inputs. The cost side is the full price of a complete course, not one session: medication, provider visits, monitoring, and any required observation. The results side is what the treatment actually did, measured before and after on a standard scale and reported in a peer-reviewed study, not on a marketing page. A credible result is one that is:

• Published and peer-reviewed, so outside experts have checked it.
• Measured on a validated scale like the PHQ-9, not a customer survey.
• Reported with the number of patients it was measured on.
• Drawn from the provider's own protocol and patients, not borrowed from a different study.

You can only run this math when a provider has published how much it improves patients. Many providers never have. For them, the price is all you get to see, and a price with no result behind it tells you nothing about whether it is worth paying.

Side-by-Side Comparison Table

The following table compares the four treatments on cost and on the results each has published. The figures come from separate real-world studies of different patients, so each treatment is measured against its own baseline, not head to head. Cost per point of improvement uses the midpoint of each cost range.

Outcomes from Mathai 2024 (at-home, 11,441 patients),¹ McInnes 2022 (IV, 537 patients),² and Marci 2025 (Spravato, 163 patients).³ Cost per point uses the midpoint of each cost range.

At-home ketamine therapy with published outcomes has the lowest cost per point of improvement, about $170, while matching IV ketamine's published results and exceeding Spravato's. IV costs more than four times as much per point of improvement, and Spravato more than ten times as much. Daily low-dose oral ketamine and at-home providers without published outcomes cannot be placed on this scale, because neither has published how much it improves patients.

Spravato (Esketamine): Cost and Published Outcomes

Spravato is the FDA-approved form of ketamine therapy, an esketamine nasal spray cleared for treatment-resistant depression and for major depression with suicidal thoughts. It is the only option here with FDA approval, and the only one that must be given in a certified clinic, where federal rules (the REMS program) require two hours of monitoring after every dose. ⁴

A full induction course is twice-weekly dosing for about four weeks. The medication alone runs roughly $4,720 to $6,785 in the first month at wholesale prices, and once the required in-clinic administration and monitoring are added, a real-world course costs about $6,000 to $10,000 without insurance.⁵

In the largest real-world study of Spravato measured on the PHQ-9 (Marci 2025, 163 patients), 18.4% of patients reached remission, with symptoms falling 4.4 points on average, the lowest published figures of the three treatments with data.³ Against the midpoint of its cost range, Spravato works out to about $1,800 for each point of improvement, more than ten times the at-home figure. It holds the only FDA approval in the group, and also the highest price for the least published improvement.

IV Ketamine: Cost and Published Outcomes

IV ketamine delivers racemic ketamine directly into the bloodstream through an infusion in a clinic, usually over 40 to 60 minutes, administered by a clinician or nurse. It is used off-label for depression and has the longest track record of any route.

A standard induction series is about six infusions over two to three weeks. At roughly $400 to $2,000 per infusion, a full series runs from about $1,600 to $12,000, depending on the clinic and whether therapy or monitoring is included.²

In the largest real-world study measured on the PHQ-9 (McInnes 2022, 537 patients), 28.9% of patients reached remission and 53.6% responded, with symptoms falling 8.7 points on average.² Against the midpoint of its cost range, IV works out to about $780 for each point of improvement, more than four times the at-home figure. The published results are close to at-home ketamine therapy's. The cost is what sets them apart.

At-Home Ketamine Therapy: Cost and Published Outcomes

At-home ketamine therapy is prescribed by a licensed clinician over telehealth and taken as a sublingual tablet or a small injection at home, with a peer treatment monitor present for every session. A full six-session course costs $1,290,⁶ the lowest of the three treatments with published results.

But at-home providers are not equal. Only one has published outcomes at scale: Mindbloom, whose peer-reviewed data on its own patients appears in the Journal of Affective Disorders (Hull 2022⁷ and Mathai 2024¹). In the larger study (Mathai 2024, 11,441 patients), 28.1% reached remission and 56.4% responded, with symptoms falling 7.6 points on average.¹ Other at-home brands such as Innerwell and BetterU charge comparable prices but have published nothing on their own protocols, so there is no way to know what their patients actually get.

Against the $1,290 course price, at-home therapy with published results works out to about $170 for each point of improvement, the lowest unit price of any treatment with data, while matching real-world IV ketamine and exceeding real-world Spravato on remission and response.

Daily Low-Dose Oral Ketamine: Cost and the Published Evidence

Daily low-dose oral ketamine refers to commercial programs, Joyous and similar, that prescribe a once-daily oral dose of racemic ketamine at sub-perceptual levels, taken indefinitely.

They are marketed mainly on price, around $129 a month.¹⁰ The problem is that no published trial has tested this protocol in a general depression population. The closest study, Irwin 2013, used once-daily oral ketamine but in 14 hospice and end-of-life patients, a group whose results do not transfer.⁸ A separate seven-patient pilot used a different molecule, oral esketamine, on a more intensive three-times-daily schedule and produced no responders and no remitters (Smith-Apeldoorn 2022).⁹

Neither tests what these programs actually sell. Because no one has published how much these programs improve patients, there is no cost per point to calculate. The monthly price is the lowest of any option, but it buys a result no study has ever measured.

What the Published Evidence Allows Us to Conclude

So which ketamine treatment offers the best outcomes for the price? On the published evidence, it is at-home ketamine therapy with proven results, at about $170 for each point of improvement, compared with roughly $780 for IV ketamine and $1,800 for Spravato. Its published remission and response rates are on par with IV ketamine and higher than Spravato's. The lowest-priced monthly options, daily low-dose oral ketamine and at-home providers without published data, fall outside the comparison, because their results have never been measured. Where outcomes have been published, value is something you can actually weigh. Where they haven't, the price is all you can see.

Mindbloom May Be Right for You If

• You want a treatment option with independently reviewed outcomes on its own protocol and patient population.
• You prefer the comfort and convenience of at-home sessions with medical oversight.
• You want a program that includes preparation, integration, and ongoing support beyond the medication itself.
• You are looking for a more affordable per-course cost relative to IV clinics or Spravato.
• You want the option of subcutaneous administration for more consistent session intensity.

IV Infusion Clinics May Be Right for You If

• You prefer in-person supervision during every session.
• You want the highest bioavailability route through intravenous delivery.
• You have access to a clinic that includes therapy or integration alongside infusions.
• You are comfortable with the per-course cost and logistics of repeated in-clinic visits.
• Your provider recommends an in-clinic setting based on your specific medical history.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.